Savara Inc (NASDAQ:SVRA) Director David A. Ramsay Purchases 40,215 Shares

Share on StockTwits

Savara Inc (NASDAQ:SVRA) Director David A. Ramsay acquired 40,215 shares of Savara stock in a transaction dated Tuesday, June 18th. The stock was purchased at an average price of $2.37 per share, with a total value of $95,309.55. Following the completion of the purchase, the director now owns 23,570 shares of the company’s stock, valued at $55,860.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

SVRA stock traded up $0.33 during trading on Wednesday, hitting $2.71. 2,067,100 shares of the company traded hands, compared to its average volume of 364,999. The company has a current ratio of 12.05, a quick ratio of 12.05 and a debt-to-equity ratio of 0.24. The stock has a market cap of $85.28 million, a P/E ratio of -2.10 and a beta of 0.95. Savara Inc has a 1 year low of $2.32 and a 1 year high of $14.06.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.05. On average, research analysts predict that Savara Inc will post -1.62 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Morgan Stanley raised its position in Savara by 224.1% during the third quarter. Morgan Stanley now owns 205,560 shares of the company’s stock valued at $2,294,000 after acquiring an additional 142,140 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in Savara by 46.9% in the first quarter. Mesirow Financial Investment Management Inc. now owns 41,332 shares of the company’s stock valued at $305,000 after purchasing an additional 13,187 shares during the period. Bank of America Corp DE grew its holdings in Savara by 59.6% in the fourth quarter. Bank of America Corp DE now owns 35,117 shares of the company’s stock valued at $266,000 after purchasing an additional 13,115 shares during the period. Geode Capital Management LLC grew its holdings in Savara by 6.2% in the fourth quarter. Geode Capital Management LLC now owns 310,498 shares of the company’s stock valued at $2,350,000 after purchasing an additional 18,171 shares during the period. Finally, Sofinnova Investments Inc. grew its holdings in Savara by 8.0% in the fourth quarter. Sofinnova Investments Inc. now owns 754,372 shares of the company’s stock valued at $5,711,000 after purchasing an additional 56,147 shares during the period. Institutional investors own 45.71% of the company’s stock.

Several research analysts have recently issued reports on the company. Zacks Investment Research cut Savara from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. BidaskClub cut Savara from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 14th. JMP Securities cut Savara from an “outperform” rating to a “market perform” rating and set a $2.60 price target for the company. in a research report on Thursday, June 13th. Roth Capital set a $10.00 price target on Savara and gave the company a “hold” rating in a research report on Tuesday, May 14th. Finally, ValuEngine upgraded Savara from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. Savara currently has a consensus rating of “Hold” and an average price target of $8.10.

ILLEGAL ACTIVITY NOTICE: This article was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4380016/savara-inc-nasdaqsvra-director-david-a-ramsay-purchases-40215-shares.html.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

See Also: Do closed-end mutual funds pay dividends?

Insider Buying and Selling by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report